Andrew Armstrong
Overview:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
Positions:
Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Professor in Surgery
Surgery, Urology
School of Medicine
Professor in Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
B.S.E. 1996
Duke University
M.D. 2000
University of Virginia School of Medicine
M.Sc. 2008
Johns Hopkins University
Internship/Residency, General Internal Medicine
University of Pennsylvania, School of Medicine
Fellowship, Division Of Oncology/Hematology
Johns Hopkins University School of Medicine
Grants:
Study title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca AB
Role
Principal Investigator
Start Date
End Date
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Administered By
Duke Cancer Institute
Awarded By
Constellation Pharmaceuticals
Role
Principal Investigator
Start Date
End Date
VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177lu-Psma-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Administered By
Duke Cancer Institute
Awarded By
Endocyte, Inc.
Role
Principal Investigator
Start Date
End Date
A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Role
Principal Investigator
Start Date
End Date
A Phase II Study of Navarixin (MK-7123) in Combination with Pembrolizumab (MK-3475) in Participants with Selected Advanced/Metastatic Solid Tumors
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Role
Principal Investigator
Start Date
End Date
Publications:
Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
<jats:p><p>Waterfall plots depicting A) the proportion of men achieving a 50% or greater PSA decline from baseline, confirmed with a subsequent value (confirmed PSA50) and B) best overall objective radiographic responses among response evaluable subjects at baseline, by RECIST 1.1 criteria.</p></jats:p>
Authors
Gupta, S; Halabi, S; Yang, Q; Roy, A; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; Wenstrup, R; Armstrong, AJ
MLA Citation
Gupta, Santosh, et al. Figure S3 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 12 Apr. 2023. Crossref, doi:10.1158/1078-0432.22596021.
URI
https://scholars.duke.edu/individual/pub1571434
Source
crossref
Published Date
DOI
10.1158/1078-0432.22596021
Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
<jats:p><p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p></jats:p>
Authors
Gupta, S; Halabi, S; Yang, Q; Roy, A; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; Wenstrup, R; Armstrong, AJ
MLA Citation
Gupta, Santosh, et al. Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 4 Apr. 2023. Crossref, doi:10.1158/1078-0432.22553341.
URI
https://scholars.duke.edu/individual/pub1571426
Source
crossref
Published Date
DOI
10.1158/1078-0432.22553341
Supplementary Method from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer
<jats:p><p>Whole-exome sequencing and analysis of CTC-DNA.</p></jats:p>
Authors
Gupta, S; Halabi, S; Kemeny, G; Anand, M; Giannakakou, P; Nanus, DM; George, DJ; Gregory, SG; Armstrong, AJ
MLA Citation
Gupta, Santosh, et al. Supplementary Method from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22527260.
URI
https://scholars.duke.edu/individual/pub1571451
Source
crossref
Published Date
DOI
10.1158/1541-7786.22527260
Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer
<jats:p><p>Top pathways enriched at baseline (N=45) and progression (N=28) during ingenuity pathway analysis (IPA, Qiagen). Selection criteria; top genes altered in >=40% of the cases.</p></jats:p>
Authors
Gupta, S; Halabi, S; Kemeny, G; Anand, M; Giannakakou, P; Nanus, DM; George, DJ; Gregory, SG; Armstrong, AJ
MLA Citation
Gupta, Santosh, et al. Table S1 from Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22527257.v1.
URI
https://scholars.duke.edu/individual/pub1571481
Source
crossref
Published Date
DOI
10.1158/1541-7786.22527257.v1
Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
<jats:p><p>CTC biomarker group incidence by PSMA optimal cutoff (AR-v7, chromosomal instability (CIN), and neuroendocrine (NE) at baseline (N=97) and progression (N=57).</p></jats:p>
Authors
Gupta, S; Halabi, S; Yang, Q; Roy, A; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, DC; Szmulewitz, RZ; Wenstrup, R; Armstrong, AJ
MLA Citation
Gupta, Santosh, et al. Table S4 from PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22438077.v1.
URI
https://scholars.duke.edu/individual/pub1571484
Source
crossref
Published Date
DOI
10.1158/1078-0432.22438077.v1
Professor of Medicine
Contact:
Duke Box 103861, Durham, NC 27710
GSRB1 Room 3006, 905 La Salle St, Durham, NC 27710